Telix finalizes acquisition of advanced therapeutic assets and cutting-edge biologics technology

Telix Pharmaceuticals has successfully finalized the acquisition of ImaginAb, a strategic move that strengthens its position in the radiopharmaceuticals and cancer therapeutics space. The acquisition, valued at $45 million upfront, brings cutting-edge biologics technology, next-generation therapeutic candidates, and a research facility in Los Angeles under Telix’s umbrella.

ImaginAb’s pipeline includes promising drug candidates targeting DLL3 and integrin αvβ6—key cancer markers associated with lung and gastrointestinal malignancies. These assets align with Telix’s commitment to advancing theranostic radiopharmaceuticals, which combine diagnostic imaging and targeted therapy for more precise cancer treatment.

The deal’s financial structure consists of a $10 million cash component, $31 million in Telix equity (2,053,311 shares valued at AU$24.3745 per share), and an additional deferred payment of up to $4 million. Moreover, Telix may pay up to $185 million in milestone-based payments, contingent on the achievement of specific development and commercialization targets.

Beyond its drug pipeline, ImaginAb brings advanced protein engineering expertise, allowing Telix to leverage innovative antibody formats designed for rapid tumor targeting and clearance. This capability is critical in radiopharmaceuticals, as it enhances the precision of radiation delivery to cancerous cells while minimizing off-target effects.

By integrating ImaginAb’s proprietary technology and research team into its operations, Telix significantly boosts its ability to develop next-generation theranostics. The acquisition not only expands its therapeutic portfolio but also solidifies its leadership in precision oncology, positioning the company for further advancements in targeted cancer treatment.